<DOC>
	<DOC>NCT00105937</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.</brief_summary>
	<brief_title>OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients</brief_title>
	<detailed_description>The objective of this study is to determine the tolerability and safety of OraVescent fentanyl when used long term to relieve breakthrough pain in opioid tolerant cancer patients.</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1880 years of age Average of 14 breakthrough pain episodes per day Opioid tolerant Histologically documented diagnosis of a malignant solid tumor or hematological malignancy Primary breakthrough pain is not related to cancer in any way Opioid or fentanyl intolerance Chronic obstructive pulmonary disease (COPD) or heart disease Sleep apnea or active brain metastases with increased cranial pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Pain</keyword>
</DOC>